Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex

Journal of Neuroscience Research

Volumn 50, Issue 6, 1997, Pages 937-945

  Lukiw, Walter J ^a   Bazan, Nicolas G ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain actin; Brain transcription; Cyclooxygenase 1 (COX l); Cyclooxygenase 2 (COX 2); Inflammation; Neocortex; NSAIDS; Prostaglandin G H synthase; RNA message; RNA stability; RT PCR

Indexed keywords

BETA ACTIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; RNA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME STABILITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEOCORTEX; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOCORTEX; PERIODICITY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VARIATION (GENETICS);

EID: 0031453714     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E     Document Type: Article

References (34)

1. Anderson K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A (1995): Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45:1441-1445.
2. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK (1994): Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci 91:5252-5256.
3. Breitner JC (1996): Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 17:789-794.
4. Chomczynski P (1993): A reagent for the single-step simultaneous isolation of RNA. DNA and proteins from cell and tissue samples. Biotechniques 15:532-536.
5. Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thai LJ, Beal MF, Howell N, Parker WJ Jr (1997): Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci 94:4526-4531.
6. Han SW, Lai ZM, Rao CV (1996): Up-regulation of cyclooxygenase-2 gene by chorionic gonadotropin in mucosal cells from human fallopian tubes. Endocrinology 137:2929-2937.
7. Hla T, Maciag T (1991): Cyclooxygenase gene expression is down regulated by heparin-binding (acidic fibroblast) growth factor-1 in human endothelial cells. J Biol Chem 266:24059-24063.
8. Hla T, Nelson K (1992): Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci 89:7384-7388.
9. Khalili K, Weinmann R (1984): Actin mRNAs in HeLa cells. J Mol Biol 180:1007-1021.
10. Kobayashi H, Sakimura R, Kuwano R, Sato S, Ikuta F, Takahashi Y, Miyatake T, Tsuji S (1990): Stability of messenger RNA in postmortem human brains and construction of human brain cDNA libraries. Mol Neurosci 2:29-34.
11. Lopez-Alberola RF, Barker WW, Harwood DG, Loewenstein DA, George-Hyslop PH, Tsuda T, Rogaeva EA, Duara R (1997): Interfamilial and intrafamilial phenotypic heterogeneity in familial Alzheimer's disease. J Geriatr Psychiatry Neurol 10:1-6.
12. Lukiw WJ, Wong L, McLachlan DRC (1990): Cytoskeletal messenger RNA stability in human neocortex: studies in normal aging and in Alzheimer's disease, Int J Neurosci 55:81-88.
13. Lukiw WJ, Rogaev EI, Wong L, Vaula G, McLachlan DRC, St. George Hyslop P (1994): Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Mol Brain Res 22:121-131.
14. Lukiw WJ, McLachlan DRC, Bazan NG (1996a): RNA message levels in normally aging and in Alzheimer's disease (AD)-affected human temporal lobe neocortex. In Fiskum G (ed): "Neurodegenerative Diseases." New York: Plenum Press, pp 141-145.
15. Lukiw WJ, Rogaev EI, Bazan NG (1996b): Synaptic and cytoskeletal RNA message levels in Alzheimer's neocortex. Alzheimer's Res 2:221-228.
16. Marcheselli VL, Bazan NG (1996): Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem 271:24794-24799.
17. McGeer PL, Schulzer M, McGeer EG (1996): Arthritis and amiintiammatory agents as possible protective factors for Alzheimer's disease; a review of 17 epidemiologic studies. Neurology 47:425-432.
18. Milliken GA, Johnson DE (1984): In: "Analysis of Messy Data. Vol. I: Designed Experiments." New York: Van Nostrand Reinhold, pp 473-512.
19. Mirra SS, Heyman A, McKeel D, Sumi SM, Grain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991): The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486.
20. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T (1985): Molecular structure of the human cytoplasmic β-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci 82:6133-6137.
21. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD (1996): Interleukin-1 beta induces prostaglandin G/H synthase 2 (cyclooxygenase 2) in primary murine astrocyte cultures. J Neurochem 66:2532-2540.
22. Oka A, Takashima S (1997): Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurons and axons. Neuroreport 8:1161-1164.
23. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995): Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55.
24. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T (1994): Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 269:11769-11775.
25. Ristmaki A, Narko K, Hla T (1996): Down-regulation of cytokineinduced cyclooxygenase 2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318:325-331.
26. Sajdel-Sulkowska EM, Majocha RE, Salim M, Zain SB, Marotta CA (1988): The postmortem Alzheimer brain is a source of structur-ally and functionally intact astrocytic messenger RNA. J Neurosci Methods 23:173-179.
27. Shaw G, Kamen R (1986): A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659-667.
28. Srivastava SK, Tetsuka T, Daphna-Iken D, Morrison AR (1994): IL-I beta stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol 267:F504-508.
29. St George-Hyslop PH, Haines JL, Farrer LA, Polinsky R, Van Broeckhoven C, Goate A, McLachlan DRC, Orr H, Bruni AC, Sorbi S, et al. (1990): Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. FAD Collaborative Study Group. Nature 347:194-197.
30. Stewart WF, Kawas C, Corrada M, Metter EJ (1997): Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-632.
31. Taylor GR, Carte GI, Crow TJ, Johnson JA, Fairbairn AF, Perry EK, Perry RH (1986): Recovery and measurement of specific RNA species from postmortem brain tissue: a general reduction in Alzheimer's disease detected by molecular hybridization. Exp Mol Pathol 44:111-116.
32. Terry RD (1983): Cortical morphometry in Alzheimer's disease. In Kutzmun R (ed): "Biological Aspects of Alzheimer's Disease." New York: Cold Spring Harbor, pp 95-98.
33. Vane J, Botting R (1987): Inflammation and the mechanism of action of antiinrtammatory drugs. FASEB J 11:89-96.
34. Zakar T, Hirst JJ, Mijovic JE, Olson DM (1995): Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells. Endocrinology 136:1610-1619.